NuVasive EVP Jason Hannon Sells 8,705 Shares (NUVA)
NuVasive (NASDAQ:NUVA) EVP Jason Hannon unloaded 8,705 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $23.99, for a total value of $208,832.95. Following the transaction, the executive vice president now directly owns 19,991 shares in the company, valued at approximately $479,584. The sale was disclosed in a filing with the SEC, which is available at this link.
NuVasive (NASDAQ:NUVA) traded down 0.04% during mid-day trading on Tuesday, hitting $24.31. 236,532 shares of the company’s stock traded hands. NuVasive has a 52 week low of $12.35 and a 52 week high of $27.20. The stock’s 50-day moving average is $24.10 and its 200-day moving average is $23.19. The company’s market cap is $1.083 billion.
NuVasive (NASDAQ:NUVA) last announced its earnings results on Tuesday, July 30th. The company reported $0.20 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.23 by $0.03. The company had revenue of $165.70 million for the quarter, compared to the consensus estimate of $161.67 million. During the same quarter last year, the company posted $0.27 earnings per share. NuVasive’s revenue was up 7.3% compared to the same quarter last year. Analysts expect that NuVasive will post $1.01 EPS for the current fiscal year.
A number of analysts have recently weighed in on NUVA shares. Analysts at Needham & Company initiated coverage on shares of NuVasive in a research note to investors on Thursday, August 8th. They set a “buy” rating and a $28.00 price target on the stock. Separately, analysts at RBC Capital raised their price target on shares of NuVasive from $23.00 to $27.00 in a research note to investors on Thursday, August 1st. They now have a “sector perform” rating on the stock. Finally, analysts at Piper Jaffray Cos. raised their price target on shares of NuVasive from $24.00 to $31.00 in a research note to investors on Thursday, August 1st. They now have an “overweight” rating on the stock. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $25.27.
NuVasive, Inc (NASDAQ:NUVA) is a medical device company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.